Vector Science & Therapeutics Corp. has announced the appointment of Russell Starr as President, effective October 5, 2026. Bill Jackson will continue in his role as Chief Executive Officer. Starr’s decision to accept his full salary in common shares, pending approval from the TSX Venture Exchange, underscores his commitment to the company’s vision.
As part of his appointment, Starr received 1,500,000 stock options, which are valid for five years. These options will vest when the company’s stock price reaches CAD $3.50, $4.50, and $5.50, based on a 10-day volume-weighted average price for each target.
Starr brings extensive experience as an entrepreneur and capital markets executive, having successfully raised over $2 billion for public companies. He has played key roles in guiding companies through complex financing and strategic initiatives, enhancing shareholder value. His connection to Vector extends beyond his new role, as he has been actively involved in advancing the company’s mission to develop pharma-grade peptides and non-opioid solutions targeting longevity and overall well-being.
Tommy Thompson, Chairman of Vector, expressed confidence in Starr’s leadership, stating, “Russell’s judgment and experience make him exactly the right partner as we enter this next phase.” Bill Jackson echoed this sentiment, noting that Starr has been instrumental in many of Vector’s achievements thus far.
In his new position, Russell Starr stated, “I’ve been deeply invested in Vector’s mission since day one, and I’m honored to take on this role at such a pivotal moment for the Company. I look forward to working alongside Bill and the rest of the team to help Vector scale now that it is producing pharma-grade peptides.”
Vector Science & Therapeutics Corp., headquartered in Mequon, Wisconsin, is focused on advancing drug delivery technology and manufacturing pharma-grade peptides for sports medicine, regenerative medicine, and pain management markets. Their products are produced under rigorous standards and are positioned for direct use by physicians.
Moving forward, the company will continue its strategic initiatives in drug delivery and peptide manufacturing, aiming for growth in the evolving medical technology landscape.
